Establishing a network of specialist Porphyria centres - effects on diagnostic activities and services

Orphanet Journal of Rare Diseases

Sverre Sandberg⁴  Jordi To-Figueras⁶  Joanne Marsden³  Jean-Charles Deybach¹  Egil Støle²  Jørild Haugen Villanger²  Aasne K Aarsand²  Mette C Tollånes⁵ 

[1] Assistance Publique-Hôpitaux de Paris, Centre Français des Porphyries, Hôpital Louis Mourier, Colombes, France AND Centre de Recherche Biomedicale Bichat-Beaujon, Université Paris Diderot, Paris, France;Norwegian Porphyria Centre (NAPOS), Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway;Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK;Norwegian Porphyria Centre (NAPOS), Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway AND Norwegian Quality Improvement of Primary Care Laboratories (NOKLUS), Section for General Practice, University of Bergen, Bergen, Norway;Norwegian Porphyria Centre (NAPOS), Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway AND Institute of Public Health and Primary Health Care, University of Bergen, Bergen, Norway;Biochemistry and Molecular Genetics Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

关键词: Specialist centre;    Porphyria;    Metabolic disease;    Diagnostics;    Activity data;   

Others  :  864176
DOI  :  10.1186/1750-1172-7-93

 received in 2012-09-26, accepted in 2012-12-05,  发布年份 2012

【 摘 要 】

Background

The porphyrias are a heterogeneous group of rare metabolic diseases. The full spectrum of porphyria diagnostics is usually performed by specialized porphyria laboratories or centres. The European Porphyria Initiative (EPI), a collaborative network of porphyria centres formed in 2001, evolved in 2007 into the European Porphyria Network (EPNET), where participating centres are required to adhere to agreed quality criteria. The aim of this study was to examine the state and distribution of porphyria diagnostic services in 2009 and to explore potential effects of increased international collaboration in the field of these rare diseases in the period 2006–2009.

Methods

Data on laboratory, diagnostic and clinical activities and services reported to EPI/EPNET in yearly activity reports during 2006 through 2009 were compared between reporting centres, and possible time trends explored.

Results

Thirty-five porphyria centres from 22 countries, five of which were non-European associate EPNET members, filed one or more activity reports to EPI/EPNET during the study period. Large variations between centres were observed in the analytical repertoire offered, numbers of analyses performed and type and number of staff engaged. The proportion of centres fulfilling the minimum criteria set by EPNET to be classified as a specialist porphyria centre increased from 80% to 94% during the study period.

Conclusions

Porphyria services are unevenly distributed, and some areas are probably still lacking in specialized porphyria services altogether. However, improvements in the quality of diagnostic services provided by porphyria centres participating in EPI/EPNET were observed during 2006 through 2009.

【 授权许可】

   
2012 Tollånes et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Puy H, Gouya L, Deybach JC: Porphyrias. Lancet 2010, 375:924-937.
• [2]Pampolos T: Inherited Metabolic Rare Disease. In Rare Diseases Epidemiology. 1st edition. Edited by Posada de la Paz M, Groft SC. Netherlands: Springer; 2010:397-431.
• [3]Deybach JC, Badminton M, Puy H, Sandberg S, Frank J, Harper P, Martasek P, Minder E, Parker S, Thunell S, Elder G: European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol Res 2006, 55(Suppl 2):S67-S73.
• [4][http://www.porphyria-europe.com/] webcite . [cited 2010 09.08]; Available from:http://www.porphyria-europe.com/ webcite
• [5]Deybach JC BM, Elder G, Parker S, Sandberg S: European Porphyria Network - Providing better healthcare for patients and their families Final report. 2010.
• [6]Whatley SD, Mason NG, Woolf JR, Newcombe RG, Elder GH, Badminton MN: Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 2009, 55:1406-1414.
• [7]Aarsand AK, Villanger JH, Stole E, Deybach JC, Marsden J, To-Figueras J, Badminton M, Elder GH, Sandberg S: European Specialist Porphyria Laboratories: Diagnostic Strategies, Analytical Quality, Clinical Interpretation, and Reporting as Assessed by an External Quality Assurance Program. Clin Chem 2011, 57:1514-1523.
• [8]Lecha M, Puy H, Deybach JC: Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4:19. BioMed Central Full Text
• [9]Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, Corrigall AV, Meissner PN, Hift RJ, Marsden JT, Ma Y, Mieli-Vergani G, Deybach JC, Puy H: C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008, 83:408-414.
• [10]Bylesjo I, Wikberg A, Andersson C: Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 2009, 69:612-618.
• [11]Tjensvoll K, Bruland O, Floderus Y, Skadberg O, Sandberg S, Apold J: Haplotype analysis of Norwegian and Swedish patients with acute intermittent porphyria (AIP): Extreme haplotype heterogeneity for the mutation R116W. Dis Markers 2003, 19:41-46.
• [12]Aarsand AK, Boman H, Sandberg S: Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem 2009, 55:795-803.
• [13]Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG, Meissner DM, Kirsch RE, Dailey HA: A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 1996, 13:95-97.
• [14]Elder G, Harper P, Badminton M, Sandberg S, Deybach JC: The Incidence of inherited porphyrias in Europe. J Inherit Metab Dis 2012. [Epub ahead of print]